Early-Stage Lung Cancer

The FDA approved alectinib as an adjuvant treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer following tumor resection and detection by an FDA-approved test.

Adjuvant therapy with alectinib prolonged DFS compared with platinum-based chemotherapy for certain patients with lung cancer, according to the agent’s manufacturer.

CHICAGO — The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes for patients with early-stage resectable non-small cell lung cancer, according to findings presented at ASCO Annual Meeting.

Patients with early-stage non-small cell lung cancer who underwent surgical resection had higher rates of long-term survival than those who received stereotactic body radiation therapy, according to study results.

Patients who received sublobar resection for early-stage non-small cell lung cancer had similar 5-year DFS rates compared with those who underwent lobectomy, according to results of a randomized phase 3 study.

Although use of limited resection or stereotactic body radiation therapy for early-stage non-small cell lung cancer had comparable odds for at least one adverse event, the overall toxicity profiles differed, according to study results.

Ravi Salgia, MD, PhD, spoke with Healio about a study assessing the safety and efficacy of three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy compared with two cycles in patients with early-stage lung cancer.

In this video, Peter J. Mazzone, MD, MPH, pulmonologist and director of the lung cancer program in the Respiratory Institute at Cleveland Clinic, discusses his presentation on the role of shared decision-making in early-stage lung cancer.

Healio spoke with Jae Y. Kim, MD, about a study presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.